Product/Composition:- | Sodium Zirconium Cyclosilicate Generics |
---|---|
Strength:- | 5g, 7g,10g sachets |
Form:- | Powder for oral suspension |
Reference Brands:- | Lokelma® (EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Sodium Zirconium Cyclosilicate (SZC), marketed as Lokelma®, is a fast-acting, selective potassium binder used to treat hyperkalemia in CKD and heart failure patients. Approved in the EU and US, it is supplied as a powder for oral suspension in 5 g and 10 g sachets.
Sodium Zirconium Cyclosilicate (SZC), marketed as Lokelma®, is a novel, highly selective potassium binder used to treat hyperkalemia in patients with chronic kidney disease, heart failure, or those on RAAS inhibitors. Approved by the FDA and EMA, it offers rapid onset and sustained potassium control with excellent tolerability. Available as a powder for oral suspension in 5 g and 10 g strengths, SZC is in high demand across EU and US pharmaceutical B2B markets. Ideal for licensing, distribution, and contract manufacturing partnerships, SZC represents a valuable addition to renal and cardiovascular therapeutic portfolios in regulated international markets.